Loading...

RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers.

1 The new converting enzyme inhibitor RHC 3659 was tested in 15 male volunteers. The study consisted of two parts: first, the ability of a single oral dose (5, 10, 20, 40 or 80 mg) to inhibit the pressor response to exogenous angiotensin I was tested with blood pressure and heart rate monitored cont...

Full description

Saved in:
Bibliographic Details
Main Authors: Burnier, M, Turini, G A, Brunner, H R, Porchet, M, Kruithof, D, Vukovich, R A, Gavras, H
Format: Artigo
Language:Inglês
Published: 1981
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC1401926/
https://ncbi.nlm.nih.gov/pubmed/6280740
Tags: Add Tag
No Tags, Be the first to tag this record!